生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

交易中 08-13 11:47:31 EDT

1,292.34

-0.42

-0.03%

最高1,305.14	最低1,290.09	成交量6.95亿
今开1,292.76	昨收1,292.76	日振幅1.16%
总市值0.00	流通市值0.00	总股本0.00
成交额39.29亿	换手率--	流通股本0.00
市净率7.972644	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1292.341,"timestamp":1786636051630,"preClose":1292.7635,"halted":0,"volume":695388293,"delay":0,"changeRate":-0.000327,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-0.422607,"latestTime":"08-13 11:47:31 EDT","open":1292.7649,"high":1305.1355,"low":1290.087,"amount":3928785639.614876,"amplitude":0.011641,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786651200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.972644,"peRate":-102.340083,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1165028117","title":"Cullinan Therapeutics旗下Zipalertinib联合化疗在Rezilient3三期试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1165028117","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165028117?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:08","pubTimestamp":1786615703,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics宣布，其研发药物Zipalertinib与化疗联合疗法，在代号为Rezilient3的III期临床试验中，成功达到了预设的主要终点。（注：根据原文内容，该句为独立核心信息，无附加段落分隔。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150020764","title":"Cullinan Therapeutics 与 Taiho Oncology 及 Taiho Pharmaceutical 联合推进 Zipalertinib 组合疗法在美国的监管审批","url":"https://stock-news.laohu8.com/highlight/detail?id=1150020764","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150020764?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:07","pubTimestamp":1786615622,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics 携手 Taiho Oncology 与 Taiho Pharmaceutical，共同启动了一项关键举措——为 Zipalertinib 联合疗法争取美国监管机构的批准。这一战略合作标志着三方将合力推动该创新药物组合在美国市场的上市进程。Cullinan Therapeutics 作为主导方，正与 Taiho Oncology 及 Taiho Pharmaceutical 紧密协作，旨在加速这一潜在疗法的审批流程，以满足未竟的医疗需求。Zipalertinib 的联合应用有望为患者带来新的治疗选择，而此次合作也凸显了各方在肿瘤学领域的深厚布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165396510","title":"Zipalertinib显著提升无进展生存期，安全性可控——Cullinan Therapeutics迎重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1165396510","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165396510?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:05","pubTimestamp":1786615513,"startTime":"0","endTime":"0","summary":"在Cullinan Therapeutics的研发管线中，Zipalertinib治疗组展现出令人瞩目的成果：无进展生存期获得显著改善，同时安全性表现可控。这一进展，无疑为肿瘤治疗领域注入了一剂强心针。试验数据表明，接受Zipalertinib治疗的患者，其疾病进展时间被有效延长，且不良反应的严重程度与发生率均维持在可管理的范围内。所以，这不仅是数字上的提升，更是对治疗策略的实质性优化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659531301","title":"AEON 拓展拉美 AI Agent 结算网络，接入哥伦比亚国家支付系统 Bre-B","url":"https://stock-news.laohu8.com/highlight/detail?id=2659531301","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659531301?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:04","pubTimestamp":1786615474,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息， AI 经济结算协议 AEON 宣布接入哥伦比亚国家即时支付系统 Bre - B ，支持用户通过 Bre - B 标准二维码使用加密资产完成支付，商户则以哥伦比亚比索（ COP ）收款。 AEON 已支持全球超 5000 万商户，本次接入进一步将 AI 结算网络延伸至拉丁美洲本地支付体系，为 AI 和 AI Agent 接入现实商业场景、通过本地支付网络完成交易与法币结算提供了基础设施支撑。 ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2282595","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","AEON","CHAT","VTHR","AIPO","BK4139","QTOC","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659137609","title":"百济神州(06160)授出合共40764股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2659137609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659137609?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:56","pubTimestamp":1786611374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年8月7日，董事会薪酬委员会根据2016期权及激励计划的条款授予362名承授人合共40,764股美国存托股份受限制股份单位。该等受限制股份单位相当于529,932股股份，约占本公告之日公司发行股份总数的0.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","LU1303224171.USD","BK1588","LU0307460666.USD","BK1161","06160","KURE","BK4585","BK4588","LU1719994722.HKD","BK4139","LU1770034418.SGD","LU0588546209.SGD","BK4526","BK1500","LU1969619763.USD","LU0828237510.HKD","LU2328871848.SGD","BK0239","LU1251922891.USD","688235","BK1583","LU0228659784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659134408","title":"华森制药(002907.SZ)：磷酸ORIC-1327滴眼液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2659134408","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659134408?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:57","pubTimestamp":1786607862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华森制药(002907.SZ)发布公告，公司控股子公司成都华森奥睿药业有限公司(以下简称“华森奥睿”)于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发的磷酸ORIC-1327滴眼液对应2个适应症共6个规格的《药物临床试验批准通知书》。磷酸ORIC-1327滴眼液(项目编号ORIP-1009)是由华森奥睿自主研发、拥有完全自主知识产权的选择性小分子抑制剂，临床拟用于青光眼及高眼压症患者的治疗。临床前研究已在新西兰兔和食蟹猴中证实该药物具有显著的降眼压作用，同时具备良好的眼部安全性，展现出良好的成药前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002907","PSYK","BMED","IBBJ","BK0239","IBBQ","BK4139","MDTX","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659185606","title":"高比例分红难敌行情低迷 REITs吸引力有待进一步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2659185606","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659185606?lang=zh_cn&edition=full","pubTime":"2026-08-13 05:44","pubTimestamp":1786571080,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["VIG","GRI","BK4585","TRUR","BK4007","URE","BK4139","BK4588","XHOA","BPRE","RIET","CFA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182429878","title":"Atara Biotherapeutics预测：2026年运营开支将同比大幅缩减","url":"https://stock-news.laohu8.com/highlight/detail?id=1182429878","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182429878?lang=zh_cn&edition=full","pubTime":"2026-08-13 05:17","pubTimestamp":1786569428,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics：据预测，2026年运营开销将较上年同期显著下滑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153393536","title":"OS Therapies拟通过私募发行最高1000万美元高级担保可转换债券——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1153393536","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153393536?lang=zh_cn&edition=full","pubTime":"2026-08-13 05:00","pubTimestamp":1786568409,"startTime":"0","endTime":"0","summary":"OS Therapies在最新提交的SEC文件中宣布，计划通过私募方式发行最高1000万美元的高级担保可转换债券。这一举措旨在为公司未来发展提供资金支持。债券的发行细节及具体条款将在后续的文件中进一步明确。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120857809","title":"OS Therapies 及其全资子公司于2026年8月10日签署证券购买协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1120857809","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120857809?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:59","pubTimestamp":1786568348,"startTime":"0","endTime":"0","summary":"OS Therapies 公司及其全资子公司，在2026年8月10日当天，正式签署了一份证券购买协议。这一重磅消息，源自美国证券交易委员会（SEC）最新披露的官方文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180540299","title":"Kailera Therapeutics旗下高剂量Ribupatide注射剂2b期临床试验完成全部入组；数据预计2027年中出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=1180540299","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180540299?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:45","pubTimestamp":1786567521,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics（股票代码：KLRA，公司全称：Kailera Therapeutics, Inc.）近日宣布，其正在进行的高剂量Ribupatide注射剂2b期临床试验已完成全部患者入组工作。这一里程碑标志着该研究迈入关键阶段。根据公司规划，相关试验数据预计将在2027年年中正式发布。Ribupatide作为一款备受关注的注射剂候选药物，此次高剂量方案的研究结果将为其后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198856529","title":"Kailera Therapeutics 向FDA提交Ribupatide口服活性IND申请，计划2027年上半年启动三期肥胖症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1198856529","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198856529?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:44","pubTimestamp":1786567448,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics 公司已正式向美国食品药品监督管理局（FDA）提交了关于Ribupatide口服活性成分的研究性新药（IND）申请。与此同时，该公司规划在2027年上半年，启动针对肥胖症的三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120415254","title":"Longeveron第二季度每股亏损0.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120415254","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120415254?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:24","pubTimestamp":1786566275,"startTime":"0","endTime":"0","summary":"美国生物科技公司Longeveron Inc（股票代码：LGVN）于8月12日披露了其第二季度财务数据。该季度运营支出达到635.3万美元，而每股收益则录得-0.19美元。这一数字揭示了公司在研发及运营方面的持续投入情况。尽管Longeveron目前尚未实现盈利，但其在再生医学领域的探索仍在持续推进，尤其针对衰老相关疾病的研究。投资者需密切关注其未来现金流表现及管线进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132587001","title":"Cue Biopharma 股东拟转售至多1,505,570股普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1132587001","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132587001?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:16","pubTimestamp":1786565772,"startTime":"0","endTime":"0","summary":"Cue Biopharma, Inc.（简称Cue Biopharma）近期向美国证券交易委员会（SEC）提交了一份文件。该文件显示，部分现有股东计划进行股份转售。具体来看，这些股东拟出售的普通股数量上限为1,505,570股。此举旨在通过二级市场实现股份流动性的释放。相关申请已按规定程序递交至监管机构，等待后续处理。市场对此反应尚不明朗，投资者可关注后续进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167820801","title":"Onconetix 提交申请，股东拟转售最多1亿股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1167820801","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167820801?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:10","pubTimestamp":1786565439,"startTime":"0","endTime":"0","summary":"路透社8月12日消息——Onconetix Inc.（纳斯达克代码：ONCO）近日对外披露，公司已向美国证券交易委员会（SEC）提交相关文件，计划允许特定股东对最多1亿股普通股进行转售。这一举措源自公司最新提交的证券注册声明，旨在为售股股东提供股份流通的通道。此次转售安排不涉及公司直接发行新股，而是由现有股东将其持有的股份在公开市场上进行处置。市场人士对此反应不一，但普遍关注该事件可能对股价带来的短期波动影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103143027","title":"RenovoRx公布2026年第二季度创纪录业绩：商业应用加速推动，季度营收环比增长61%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103143027","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103143027?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:06","pubTimestamp":1786565203,"startTime":"0","endTime":"0","summary":"RenovoRx Inc（股票代码：RNXT）近日发布2026年第二季度财报，交出了一份亮眼的成绩单。公司不仅实现了创纪录的季度营收，更展现出强劲的增长势头——这一成绩的背后，是商业应用范围的持续扩大与市场接纳度的显著提升。具体来看，公司第二季度营收较上一季度激增61%，这无疑为投资者注入了一剂强心针。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199559944","title":"Armata Pharmaceuticals公布2026年第二季度财务业绩并发布公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1199559944","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199559944?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:06","pubTimestamp":1786565185,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals（股票代码：ARMP）今日正式披露了2026年第二季度的财务报告，并同步更新了公司近期的业务进展与战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171371738","title":"Aligos Therapeutics宣布：合作伙伴Amoytop在中国启动潜在同类最佳反义寡核苷酸Alg-170675的1期临床首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1171371738","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171371738?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:06","pubTimestamp":1786565174,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics, Inc.（ALGS）今日宣布，其合作伙伴Amoytop已在中国完成了潜在同类最佳反义寡核苷酸Alg-170675的1期临床研究首例受试者给药。这一里程碑标志着该候选药物正式进入人体试验阶段，为后续开发铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173205729","title":"Outlook Therapeutics 终止与H.C. Wainwright的ATM发行协议，撤回2026年5月13日招股书补充文件——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1173205729","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173205729?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:04","pubTimestamp":1786565050,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.宣布，已正式终止其与H.C. Wainwright & Co., LLC签订的ATM发行协议。这一决定，伴随着对2026年5月13日相关招股说明书补充文件的撤回，已在最新提交给美国证券交易委员会的文件中明确披露。然而，Outlook Therapeutics并未在简短的文件中透露终止背后的具体原因，也未说明后续是否会寻求其他替代性融资渠道。回溯来看，这份最初于2026年5月13日生效的招股书补充文件，曾为公司与H.C. Wainwright的合作设定了明确的框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136247811","title":"Outlook Therapeutics 募资投向：助力Lytenava美国上市、补充运营资金及企业一般用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1136247811","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136247811?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:02","pubTimestamp":1786564929,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics 宣布，其最新融资所得将用于支持核心产品Lytenava在美国的上市推广，同时补充公司运营资本，并满足企业日常运营及一般性开支需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0311},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.1331},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}